Vermont Center on Behavior and Health, Burlington, VT, USA.
Department of Psychiatry, University of Vermont, University Health Center, 1 S. Prospect St., Burlington, VT, 05401, USA.
Harm Reduct J. 2024 Apr 5;21(1):76. doi: 10.1186/s12954-024-00995-y.
Understanding current substance use practices is critical to reduce and prevent overdose deaths among individuals at increased risk including persons who use and inject drugs. Because individuals participating in harm reduction and syringe service programs are actively using drugs and vary in treatment participation, information on their current drug use and preferred drugs provides a unique window into the drug use ecology of communities that can inform future intervention services and treatment provision.
Between March and June 2023, 150 participants in a harm reduction program in Burlington, Vermont completed a survey examining sociodemographics; treatment and medication for opioid use disorder (MOUD) status; substance use; injection information; overdose information; and mental health, medical, and health information. Descriptive analyses assessed overall findings. Comparisons between primary drug subgroups (stimulants, opioids, stimulants-opioids) of past-three-month drug use and treatment participation were analyzed using chi-square and Fisher's exact test.
Most participants reported being unhoused or unstable housing (80.7%) and unemployed (64.0%) or on disability (21.3%). The drug with the greatest proportion of participants reporting past three-month use was crack cocaine (83.3%). Fentanyl use was reported by 69.3% of participants and xylazine by 38.0% of participants. High rates of stimulant use were reported across all participants independent of whether stimulants were a participant's primary drug. Fentanyl, heroin, and xylazine use was less common in the stimulants subgroup compared to opioid-containing subgroups (p < .001). Current- and past-year MOUD treatment was reported by 58.0% and 77.3% of participants. Emergency rooms were the most common past-year medical treatment location (48.7%; M = 2.72 visits).
Findings indicate high rates of polysubstance use and the underrecognized effects of stimulant use among people who use drugs-including its notable and increasing role in drug-overdose deaths. Crack cocaine was the most used stimulant, a geographical difference from much of the US where methamphetamine is most common. With the increasing prevalence of fentanyl-adulterated stimulants and differences in opioid use observed between subgroups, these findings highlight the importance and necessity of harm reduction interventions (e.g., drug checking services, fentanyl test strips) and effective treatment for individuals using stimulants alongside MOUD treatment.
了解当前的物质使用情况对于减少和预防包括高危人群在内的个体(包括使用和注射毒品的人群)的药物过量死亡至关重要。由于参与减少伤害和注射器服务项目的个体正在积极使用毒品,并且在治疗参与方面存在差异,因此有关其当前药物使用和首选药物的信息为社区的药物使用生态系统提供了一个独特的窗口,这可以为未来的干预服务和治疗提供信息。
2023 年 3 月至 6 月期间,佛蒙特州伯灵顿的一项减少伤害计划中的 150 名参与者完成了一项调查,调查内容包括社会人口统计学信息、阿片类药物使用障碍(MOUD)的治疗和药物治疗状况、物质使用情况、注射信息、药物过量信息以及心理健康、医疗和健康信息。描述性分析评估了总体结果。使用卡方检验和 Fisher 确切检验分析了过去三个月药物使用和治疗参与情况的主要药物亚组(兴奋剂、阿片类药物、兴奋剂-阿片类药物)之间的比较。
大多数参与者报告无家可归或住房不稳定(80.7%)和失业(64.0%)或残疾(21.3%)。报告过去三个月使用的药物中,可卡因使用率最高(83.3%)。69.3%的参与者报告使用芬太尼,38.0%的参与者报告使用唑拉西泮。所有参与者报告的兴奋剂使用率都很高,无论兴奋剂是否是参与者的主要药物。与含有阿片类药物的亚组相比,芬太尼、海洛因和唑拉西泮的使用率在兴奋剂亚组中较低(p<.001)。58.0%和 77.3%的参与者报告目前和过去一年接受 MOUD 治疗。急诊室是过去一年最常见的医疗治疗地点(48.7%;M=2.72 次就诊)。
研究结果表明,药物使用人群中存在高比例的多药物使用以及兴奋剂使用的未被充分认识到的影响,包括兴奋剂在药物过量死亡中的显著且不断增加的作用。可卡因是最常用的兴奋剂,这与美国大部分地区(最常用的是甲基苯丙胺)的情况不同。鉴于芬太尼掺假兴奋剂的流行率不断上升,以及不同亚组之间阿片类药物使用情况的差异,这些发现强调了减少伤害干预(例如药物检测服务、芬太尼检测条)和针对同时使用兴奋剂和 MOUD 治疗的个体的有效治疗的重要性和必要性。